- The market is expanding due to increased demand for plasma-derived therapies in treating conditions like hemophilia, immunodeficiency disorders, and autoimmune diseases, supported by rising awareness and advancements in transfusion medicine
- Technological advancements in blood collection, fractionation, and cold chain logistics are enhancing product quality and shelf life, encouraging wider adoption across hospitals, trauma centers, and diagnostic laboratories globally
- South Africa is expected to dominate the blood plasma & plasma derived medicinal products market with 29.62% share due to improved healthcare infrastructure, rising demand for plasma therapies, increased government support, and growing prevalence of chronic and infectious diseases
- South Africa is expected to be the fastest growing region in the blood plasma & plasma derived medicinal products market due to increasing healthcare investments, rising prevalence of chronic and infectious diseases, improved diagnostic facilities, growing awareness about blood safety, and government initiatives to boost plasma therapy accessibility and infrastructure
- The immunoglobulins segment is expected to dominate the blood plasma & plasma derived medicinal products market with a 42.41% share in 2025 due to rising demand for targeted therapies, improved purification technologies, and increasing prevalence of immune-related disorders
